An 8-year clinical study conducted by one of the companies that markets a blue scorpion venom cancer drug reported a 90% success rate for more than 8,000 patients with various forms and severity of the disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.